Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Cardiology
•
Advanced Heart Failure and Transplant
Are there other scenarios besides prior history of TIA or stroke or LV dysfunction in which systemic anticoagulation for LV non-compaction would be considered?
Related Questions
What are your top takeaways from ISHLT 2024?
What is your approach to anticoagulation in patients with hypertrophic cardiomyopathy and an apical aneurysm?
Would it be reasonable to begin considering GLP1 RAs or finerenone for patients with heart failure with recovered LVEF in light of recent trials such as SELECT and FINEARTS-HF showing some success in HFpEF and HFmrEF populations?
What are standard selection criteria for patients who are eligible for heart transplantation?
How do you choose between finerenone and traditional steroidal MRAs for patients with heart failure and mildly reduced or preserved EF, considering recent results showing finerenone's efficacy in reducing heart failure events?
What are your top takeaways from ACC 2024?
Should there be a role for sacubitril-valsartan in the management of patients with heart failure with preserved ejection fraction?
What patient characteristics prompt you to prescribe vericiguat for patients with heart failure with reduced ejection fraction who are already on standard therapy?
Do you routinely check digoxin levels, and if so, when would you consider using Digibind in chronic digoxin use patients?
How do you manage patients with central sleep apnea due to heart failure with reduced ejection fraction?
